Chong Kun Dang Pharmaceutical Corp. (185750) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Chong Kun Dang Pharmaceutical Corp (CKD Pharma) manufactures, distributes, imports, and exports prescription drugs, over-the-counter (OTC) drugs, health supplements, and consumer health products. The company's product portfolio includes prescription drugs for the central nervous system, cardiovascular, anti-infective, and oncology therapeutic areas. Its over-the-counter (OTC) drugs include vitamins and minerals, anemia treatments, nonsteroidal anti-inflammatory drugs, liver protective agents, and musculoskeletal and gastrointestinal system remedies. It has a manufacturing facility in Cheonan City, South Korea. The company has a global business presence, with operations in Asia, the Middle East, North Africa, and the European Union. CKD Pharma is headquartered in Seoul, South Korea.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Standard Bank Group Ltd - Key Facts
Standard Bank Group Ltd - Key Employees
Standard Bank Group Ltd - Key Employee Biographies
Standard Bank Group Ltd - Major Products and Services
Standard Bank Group Ltd - History
Standard Bank Group Ltd - Company Statement
Standard Bank Group Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Standard Bank Group Ltd - Business Description
Business Segment: Business & Commercial Banking
Overview
Performance
Key Stats
Business Segment: Central and Other
Overview
Performance
Key Stats
Business Segment: Corporate & Investment Banking
Overview
Performance
Key Stats
Business Segment: ICBCS
Overview
Performance
Key Stats
Business Segment: Insurance & Asset Management
Overview
Performance
Key Stats
Business Segment: Personal & Private Banking
Overview
Performance
Key Stats
Geographical Segment: Africa Regions and International
Performance
Geographical Segment: South Africa
Performance
Standard Bank Group Ltd - Corporate Strategy
Standard Bank Group Ltd - SWOT Analysis
SWOT Analysis - Overview
Standard Bank Group Ltd - Strengths
Standard Bank Group Ltd - Weaknesses
Standard Bank Group Ltd - Opportunities
Standard Bank Group Ltd - Threats
Standard Bank Group Ltd - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Standard Bank Group Ltd, Recent Deals Summary
Section 4 - Company’s Recent Developments
Jun 11, 2026: Mulilo Makes Further Inroads With Hartebeesfontein BESS Financial Close
Jun 10, 2026: Africa’s Power Shift: Renewables Outpace Non-Renewable Energy
Apr 20, 2026: Mulilo Achieves Financial Close On 380 MW Solar Project in Beaufort West, Western Cape
Mar 06, 2026: Lyra Energy commences construction of 255MW Thakadu solar facility
Sep 30, 2025: Eaglestone Advises Red Rocket South Africa on Tournee Solar PV Park Project
Aug 18, 2025: Standard Bank Enables Seriti Green’s Mpumalanga Based Ummbila Emoyeni to Increase Generation Capacity, Create Jobs and Economic Opportunity
Jun 06, 2025: Standard Bank and Noa Team Up to Unlock Capital for Energy Transition With Landmark Guarantee Facility on 349MW Solar PV Project
Section 5 - Appendix
Methodology
Ratio Definitions
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
Standard Bank Group Ltd, Key Facts
Standard Bank Group Ltd, Key Employees
Standard Bank Group Ltd, Key Employee Biographies
Standard Bank Group Ltd, Major Products and Services
Standard Bank Group Ltd, History
Standard Bank Group Ltd, Other Locations
Standard Bank Group Ltd, Subsidiaries
Standard Bank Group Ltd, Key Competitors
Standard Bank Group Ltd, Ratios based on current share price
Standard Bank Group Ltd, Annual Ratios
Standard Bank Group Ltd, Interim Ratios
Standard Bank Group Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Standard Bank Group Ltd, Performance Chart (2021 - 2025)
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net